{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:27:57Z","timestamp":1762100877299},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,12,8]],"date-time":"2008-12-08T00:00:00Z","timestamp":1228694400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1007\/s11940-009-0004-x","type":"journal-article","created":{"date-parts":[[2008,12,7]],"date-time":"2008-12-07T09:10:00Z","timestamp":1228641000000},"page":"24-31","source":"Crossref","is-referenced-by-count":6,"title":["Is botulinum toxin useful in treating headache? No"],"prefix":"10.1007","volume":"11","author":[{"given":"Mark","family":"Obermann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Christoph","family":"Diener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,12,8]]},"reference":[{"key":"4_CR1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1152\/physrev.2000.80.2.717","volume":"80","author":"G. Schiavo","year":"2000","unstructured":"Schiavo G, Matteoli M, Montecucco C: Neurotoxins affecting neuroexocytosis. Physiol Rev 2000, 80:717\u2013766.","journal-title":"Physiol Rev"},{"key":"4_CR2","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jama.285.8.1059","volume":"285","author":"S.S. Arnon","year":"2001","unstructured":"Arnon SS, Schechter R, Inglesby TV, et al.: Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001, 285:1059\u20131070.","journal-title":"JAMA"},{"key":"4_CR3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0014-5793(93)80448-4","volume":"335","author":"G. Schiavo","year":"1993","unstructured":"Schiavo G, Santucci A, Dasgupta BR, et al.: Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. FEBS Lett 1993, 335:99\u2013103.","journal-title":"FEBS Lett"},{"key":"4_CR4","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0161-6420(80)35127-0","volume":"87","author":"A.B. Scott","year":"1980","unstructured":"Scott AB: Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980, 87:1044\u20131049.","journal-title":"Ophthalmology"},{"key":"4_CR5","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJM199907083410209","volume":"341","author":"M. Hallett","year":"1999","unstructured":"Hallett M: One man\u2019s poison\u2014clinical applications of botulinum toxin. N Engl J Med 1999, 341:118\u2013120.","journal-title":"N Engl J Med"},{"issue":"8501","key":"4_CR6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(86)92070-2","volume":"2","author":"J.K. Tsui","year":"1986","unstructured":"Tsui JK, Eisen A, Stoessl AJ, et al.: Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 1986, 2(8501):245\u2013247.","journal-title":"Lancet"},{"key":"4_CR7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/mds.870020402","volume":"2","author":"M.F. Brin","year":"1987","unstructured":"Brin MF, Fahn S, Moskowitz C, et al.: Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 1987, 2:237\u2013254.","journal-title":"Mov Disord"},{"issue":"Suppl1","key":"4_CR8","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1046\/j.1526-4610.43.7s.3.x","volume":"43","author":"K.R. Aoki","year":"2003","unstructured":"Aoki KR: Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003, 43(Suppl 1):S9\u2013S15.","journal-title":"Headache"},{"issue":"Suppl1","key":"4_CR9","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1046\/j.1526-4610.43.7s.1.x","volume":"43","author":"S.D. Silberstein","year":"2003","unstructured":"Silberstein SD, Aoki KR: Botulinum toxin type A: myths, facts, and current research [editorial]. Headache 2003, 43(Suppl 1):S1.","journal-title":"Headache"},{"key":"4_CR10","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1123654","volume":"312","author":"M. Dong","year":"2006","unstructured":"Dong M, Yeh F, Tepp WH, et al.: SV2 is the protein receptor for botulinum neurotoxin A. Science 2006, 312:592\u2013596.","journal-title":"Science"},{"key":"4_CR11","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.febslet.2006.02.074","volume":"580","author":"S. Mahrhold","year":"2006","unstructured":"Mahrhold S, Rummel A, Bigalke H, et al.: The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett 2006, 580:2011\u20132014.","journal-title":"FEBS Lett"},{"key":"4_CR12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/PL00004951","volume":"355","author":"K. Wohlfarth","year":"1997","unstructured":"Wohlfarth K, Goschel H, Frevert J, et al.: Botulinum A toxins: units versus units. Naunyn Schmiedebergs Arch Pharmacol 1997, 355:335\u2013340.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"4_CR13","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/mds.10420","volume":"18","author":"F. Mancini","year":"2003","unstructured":"Mancini F, Zangaglia R, Cristina S, et al.: Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 2003, 18:685\u2013688.","journal-title":"Mov Disord"},{"key":"4_CR14","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1365-2133.1997.tb02139.x","volume":"136","author":"P. Schnider","year":"1997","unstructured":"Schnider P, Binder M, Auff E, et al.: Double-blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms. Br J Dermatol 1997, 136:548\u2013552.","journal-title":"Br J Dermatol"},{"key":"4_CR15","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2165\/00023210-200115100-00001","volume":"15","author":"L. Edvinsson","year":"2001","unstructured":"Edvinsson L: Calcitonin gene-related peptide (CGRP) and the pathophysiology of headache: therapeutic implications. CNS Drugs 2001, 15:745\u2013753.","journal-title":"CNS Drugs"},{"key":"4_CR16","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0021-5155(99)00197-5","volume":"44","author":"H. Ishikawa","year":"2000","unstructured":"Ishikawa H, Mitsui Y, Yoshitomi T, et al.: Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol 2000, 44:106\u2013109.","journal-title":"Jpn J Ophthalmol"},{"key":"4_CR17","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0041-0101(99)00153-1","volume":"38","author":"M.J. Welch","year":"2000","unstructured":"Welch MJ, Purkiss JR, Foster KA: Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000, 38:245\u2013258.","journal-title":"Toxicon"},{"key":"4_CR18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1526-4610.2004.04007.x","volume":"44","author":"P.L. Durham","year":"2004","unstructured":"Durham PL, Cady R: Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004, 44:35\u201342; discussion 42\u201343.","journal-title":"Headache"},{"key":"4_CR19","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S0022-5347(05)00322-8","volume":"175","author":"D.E. Rapp","year":"2006","unstructured":"Rapp DE, Turk KW, Bales GT, Cook SP: Botulinum toxin type A inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol 2006, 175:1138\u20131142.","journal-title":"J Urol"},{"key":"4_CR20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pain.2003.10.008","volume":"107","author":"M. Cui","year":"2004","unstructured":"Cui M, Khanijou S, Rubino J, Aoki KR: Subcutaneous administration of botulinum toxin A reduces formalininduced pain. Pain 2004, 107:125\u2013133.","journal-title":"Pain"},{"key":"4_CR21","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1526-4610.2004.04155.x","volume":"44","author":"K.M.A. Welch","year":"2004","unstructured":"Welch KMA: Botulinum toxin type A for the treatment of headache: con. Headache 2004, 44:831\u2013833.","journal-title":"Headache"},{"key":"4_CR22","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1046\/j.1526-4610.2002.02146.x","volume":"42","author":"M. Nicolodi","year":"2002","unstructured":"Nicolodi M, Galeotti N, Ghelardini C, et al.: Central cholinergic challenging of migraine by testing secondgeneration anticholinesterase drugs. Headache 2002, 42:596\u2013602.","journal-title":"Headache"},{"key":"4_CR23","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/0024-3205(89)90127-6","volume":"45","author":"M.D. Smith","year":"1989","unstructured":"Smith MD, Yang XH, Nha JY, Buccafusco JJ: Antinociceptive effect of spinal cholinergic stimulation: interaction with substance P. Life Sci 1989, 45:1255\u20131261.","journal-title":"Life Sci"},{"key":"4_CR24","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/sj.bjp.0703268","volume":"129","author":"C. Ghelardini","year":"2000","unstructured":"Ghelardini C, Galeotti N, Bartolini A: Loss of muscarinic antinociception by antisense inhibition of M(1) receptors. Br J Pharmacol 2000, 129:1633\u20131640.","journal-title":"Br J Pharmacol"},{"key":"4_CR25","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1212\/01.WNL.0000086374.92906.6A","volume":"61","author":"B. Voller","year":"2003","unstructured":"Voller B, Sycha T, Gustorff B, et al.: A randomized, doubleblind, placebo controlled study on analgesic effects of botulinum toxin A. Neurology 2003, 61:940\u2013944.","journal-title":"Neurology"},{"key":"4_CR26","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0022-510X(02)00313-1","volume":"205","author":"W. Blersch","year":"2002","unstructured":"Blersch W, Schulte-Mattler WJ, Przywara S, et al.: Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study. J Neurol Sci 2002, 205:59\u201363.","journal-title":"J Neurol Sci"},{"key":"4_CR27","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jns.2007.03.023","volume":"260","author":"W.J. Schulte-Mattler","year":"2007","unstructured":"Schulte-Mattler WJ, Opatz O, Blersch W, et al.: Botulinum toxin A does not alter capsaicin-induced pain perception in human skin. J Neurol Sci 2007, 260:38\u201342.","journal-title":"J Neurol Sci"},{"key":"4_CR28","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s00415-003-0971-x","volume":"250","author":"H.H. Kramer","year":"2003","unstructured":"Kramer HH, Angerer C, Erbguth F, et al.: Botulinum toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J Neurol 2003, 250:188\u2013193.","journal-title":"J Neurol"},{"key":"4_CR29","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1213\/01.ane.0000194447.46763.73","volume":"102","author":"T. Sycha","year":"2006","unstructured":"Sycha T, Samal D, Chizh B, et al.: A lack of antinociceptive or antiinflammatory effect of botulinum toxin A in an inflammatory human pain model. Anesth Analg 2006, 102:509\u2013516.","journal-title":"Anesth Analg"},{"key":"4_CR30","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.pain.2006.04.014","volume":"122","author":"P. Gazerani","year":"2006","unstructured":"Gazerani P, Staahl C, Drewes AM, Arendt-Nielsen L: The effects of botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain 2006, 122:315\u2013325.","journal-title":"Pain"},{"key":"4_CR31","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/1531-8249(200005)47:5<614::AID-ANA9>3.0.CO;2-N","volume":"47","author":"R. Burstein","year":"2000","unstructured":"Burstein R, Yarnitsky D, Goor-Aryeh I, et al.: An association between migraine and cutaneous allodynia. Ann Neurol 2000, 47:614\u2013624.","journal-title":"Ann Neurol"},{"key":"4_CR32","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1046\/j.1526-4610.2003.03115.x","volume":"43","author":"R.W. Evans","year":"2003","unstructured":"Evans RW, Blumenfeld A: Botulinum toxin injections for headache. Headache 2003, 43:682\u2013685.","journal-title":"Headache"},{"issue":"Suppl1","key":"4_CR33","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1046\/j.1526-4610.43.7s.5.x","volume":"43","author":"D.W. Dodick","year":"2003","unstructured":"Dodick DW: Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: from bench to bedside. Headache 2003, 43(Suppl 1):S25\u2013S33.","journal-title":"Headache"},{"key":"4_CR34","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/j.1526-4610.2004.04154.x","volume":"44","author":"A. Blumenfeld","year":"2004","unstructured":"Blumenfeld A: Botulinum toxin type A for the treatment of headache: pro. Headache 2004, 44:825\u2013830.","journal-title":"Headache"},{"key":"4_CR35","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1526-4610.2000.00066.x","volume":"40","author":"S. Silberstein","year":"2000","unstructured":"Silberstein S, Mathew N, Saper J, Jenkins S: Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 2000, 40:445\u2013450.","journal-title":"Headache"},{"key":"4_CR36","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1468-2982.2004.00641.x","volume":"24","author":"W.G. Ondo","year":"2004","unstructured":"Ondo WG, Vuong KD, Derman HS: Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. Cephalalgia 2004, 24:60\u201365.","journal-title":"Cephalalgia"},{"key":"4_CR37","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1067\/mhn.2000.110960","volume":"123","author":"W.J. Binder","year":"2000","unstructured":"Binder WJ, Brin MF, Blitzer A, et al.: Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 2000, 123:669\u2013676.","journal-title":"Otolaryngol Head Neck Surg"},{"key":"4_CR38","first-page":"1199","volume":"84","author":"N. Poungvarin","year":"2001","unstructured":"Poungvarin N: The first world report of botulinum A toxin injection for status migrainosus. J Med Assoc Thai 2001, 84:1199\u20131203.","journal-title":"J Med Assoc Thai"},{"key":"4_CR39","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1212\/WNL.53.7.1439","volume":"53","author":"A. Brashear","year":"1999","unstructured":"Brashear A, Lew MF, Dykstra DD, et al.: Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999, 53:1439\u20131446.","journal-title":"Neurology"},{"key":"4_CR40","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1468-2982.2007.01295.x","volume":"27","author":"C. Fernandez-de-las-Penas","year":"2007","unstructured":"Fernandez-de-las-Penas C, Cuadrado ML, Arendt-Nielsen L, et al.: Myofascial trigger points and sensitization: an updated pain model for tension-type headache. Cephalalgia 2007, 27:383\u2013393.","journal-title":"Cephalalgia"},{"key":"4_CR41","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/brain\/118.2.523","volume":"118","author":"F. Sakai","year":"1995","unstructured":"Sakai F, Ebihara S, Akiyama M, Horikawa M: Pericranial muscle hardness in tension-type headache. A non-invasive measurement method and its clinical application. Brain 1995, 118:523\u2013531.","journal-title":"Brain"},{"key":"4_CR42","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ana.410280213","volume":"28","author":"P.J. Goadsby","year":"1990","unstructured":"Goadsby PJ, Edvinsson L, Ekman R: Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990, 28:183\u2013187.","journal-title":"Ann Neurol"},{"key":"4_CR43","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1526-4610.2007.00963.x","volume":"48","author":"F.G. Freitag","year":"2008","unstructured":"Freitag FG, Diamond S, Diamond M, Urban G: Botulinum toxin type A in the treatment of chronic migraine without medication overuse. Headache 2008, 48:201\u2013209.","journal-title":"Headache"},{"key":"4_CR44","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1526-4610.2005.05068.x","volume":"45","author":"D.W. Dodick","year":"2005","unstructured":"Dodick DW, Mauskop A, Elkind AH, et al.: Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 2005, 45:315\u2013324.","journal-title":"Headache"},{"key":"4_CR45","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1212\/01.wnl.0000311391.00944.c4","volume":"70","author":"D.M. Simpson","year":"2008","unstructured":"Simpson DM, Gracies JM, Graham HK, et al.: Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 70:1691\u20131698.","journal-title":"Neurology"},{"key":"4_CR46","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s10194-003-0049-2","volume":"4","author":"N. Barrientos","year":"2003","unstructured":"Barrientos N, Chana P: Botulinum toxin type A in prophylactic treatment of migraine headaches: a preliminary study. J Headache Pain 2003, 4:146\u2013151.","journal-title":"J Headache Pain"},{"key":"4_CR47","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1468-2982.2004.00754.x","volume":"24","author":"S. Evers","year":"2004","unstructured":"Evers S, Vollmer-Haase J, Schwaag S, et al.: Botulinum toxin A in the prophylactic treatment of migraine-a randomized, double-blind, placebo-controlled study. Cephalalgia 2004, 24:838\u2013843.","journal-title":"Cephalalgia"},{"key":"4_CR48","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.jpain.2006.03.002","volume":"7","author":"A.H. Elkind","year":"2006","unstructured":"Elkind AH, O\u2019Carroll P, Blumenfeld A, et al.: A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J Pain 2006, 7:688\u2013696.","journal-title":"J Pain"},{"key":"4_CR49","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1468-2982.2007.01315.x","volume":"27","author":"M. Relja","year":"2007","unstructured":"Relja M, Poole AC, Schoenen J, et al.: A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia 2007, 27:492\u2013503.","journal-title":"Cephalalgia"},{"key":"4_CR50","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1526-4610.2007.00853.x","volume":"47","author":"S.K. Aurora","year":"2007","unstructured":"Aurora SK, Gawel M, Brandes JL, et al.: Botulinum toxin type A prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache 2007, 47:486\u2013499.","journal-title":"Headache"},{"key":"4_CR51","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1526-4610.2007.00949.x","volume":"48","author":"A.M. Blumenfeld","year":"2008","unstructured":"Blumenfeld AM, Schim JD, Chippendale TJ: Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache 2008, 48:210\u2013220.","journal-title":"Headache"},{"key":"4_CR52","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1526-4637.2006.00168.x","volume":"8","author":"J.R. Saper","year":"2007","unstructured":"Saper JR, Mathew NT, Loder EW, et al.: A double-blind, randomized, placebo-controlled comparison of botulinum toxin type A injection sites and doses in the prevention of episodic migraine. Pain Med 2007, 8:478\u2013485.","journal-title":"Pain Med"},{"key":"4_CR53","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1046\/j.1526-4610.2000.00044.x","volume":"40","author":"J.D. Rollnik","year":"2000","unstructured":"Rollnik JD, Tanneberger O, Schubert M, et al.: Treatment of tension-type headache with botulinum toxin type A: a double-blind, placebo-controlled study. Headache 2000, 40:300\u2013305.","journal-title":"Headache"},{"key":"4_CR54","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1046\/j.1526-4610.2001.041007658.x","volume":"41","author":"W.J. Schmitt","year":"2001","unstructured":"Schmitt WJ, Slowey E, Fravi N, et al.: Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trial. Headache 2001, 41:658\u2013664.","journal-title":"Headache"},{"key":"4_CR55","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1468-2982.2004.00738.x","volume":"24","author":"M. Padberg","year":"2004","unstructured":"Padberg M, de Bruijn SF, de Haan RJ, Tavy DL: Treatment of chronic tension-type headache with botulinum toxin: a double-blind, placebo-controlled clinical trial. Cephalalgia 2004, 24:675\u2013680.","journal-title":"Cephalalgia"},{"key":"4_CR56","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.pain.2004.01.016","volume":"109","author":"W.J. Schulte-Mattler","year":"2004","unstructured":"Schulte-Mattler WJ, Krack P: Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. Pain 2004, 109:110\u2013114.","journal-title":"Pain"},{"key":"4_CR57","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1468-2982.2006.01114.x","volume":"26","author":"S.D. Silberstein","year":"2006","unstructured":"Silberstein SD, Gobel H, Jensen R, et al.: Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia 2006, 26:790\u2013800.","journal-title":"Cephalalgia"},{"key":"4_CR58","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1468-1331.2007.02051.x","volume":"15","author":"A. Straube","year":"2008","unstructured":"Straube A, Empl M, Ceballos-Baumann A, et al.: Pericranial injection of botulinum toxin type A (Dysport) for tension-type headache-a multicentre, double-blind, randomized, placebo-controlled study. Eur J Neurol 2008, 15:205\u2013213.","journal-title":"Eur J Neurol"},{"issue":"Suppl1","key":"4_CR59","first-page":"9","volume":"24","author":"Headache Classification Subcommittee of the International Headache Society","year":"2004","unstructured":"Headache Classification Subcommittee of the International Headache Society: The International Classification of Headache Disorders, 2nd edition. Cephalalgia 2004, 24(Suppl 1):9\u2013160.","journal-title":"Cephalalgia"},{"key":"4_CR60","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1526-4610.2005.05066.x","volume":"45","author":"N.T. Mathew","year":"2005","unstructured":"Mathew NT, Frishberg BM, Gawel M, et al.: Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 2005, 45:293\u2013307.","journal-title":"Headache"},{"key":"4_CR61","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.4065\/80.9.1126","volume":"80","author":"S.D. Silberstein","year":"2005","unstructured":"Silberstein SD, Stark SR, Lucas SM, et al.: Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005, 80:1126\u20131137.","journal-title":"Mayo Clin Proc"},{"key":"4_CR62","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1093\/brain\/awn116","volume":"131","author":"B.S. Oken","year":"2008","unstructured":"Oken BS: Placebo effects: clinical aspects and neurobiology. Brain 2008, 131:2812\u20132823.","journal-title":"Brain"},{"key":"4_CR63","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1046\/j.1526-4610.2002.02155.x","volume":"42","author":"S. Solomon","year":"2002","unstructured":"Solomon S: A review of mechanisms of response to pain therapy: why voodoo works. Headache 2002, 42:656\u2013662.","journal-title":"Headache"},{"key":"4_CR64","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00228-005-0088-5","volume":"62","author":"A. Macedo","year":"2006","unstructured":"Macedo A, Farre M, Banos JE: A meta-analysis of the placebo response in acute migraine and how this response may be influenced by some of the characteristics of clinical trials. Eur J Clin Pharmacol 2006, 62:161\u2013172.","journal-title":"Eur J Clin Pharmacol"},{"key":"4_CR65","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.pain.2006.12.006","volume":"128","author":"K. Linde","year":"2007","unstructured":"Linde K, Witt CM, Streng A, et al.: The impact of patient expectations on outcomes in four randomized controlled trials of acupuncture in patients with chronic pain. Pain 2007, 128:264\u2013271.","journal-title":"Pain"},{"key":"4_CR66","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1474-4422(06)70382-9","volume":"5","author":"H.C. Diener","year":"2006","unstructured":"Diener HC, Kronfeld K, Boewing G, et al.: Efficacy of acupuncture for the prophylaxis of migraine: a multicentre randomised controlled clinical trial. Lancet Neurol 2006, 5:310\u2013316.","journal-title":"Lancet Neurol"},{"key":"4_CR67","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s10194-007-0416-5","volume":"8","author":"H.G. Endres","year":"2007","unstructured":"Endres HG, Bowing G, Diener HC, et al.: Acupuncture for tension-type headache: a multicentre, sham-controlled, patient- and observer-blinded, randomised trial. J Headache Pain 2007, 8:306\u2013314.","journal-title":"J Headache Pain"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-009-0004-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-009-0004-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-009-0004-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T06:29:27Z","timestamp":1709620167000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-009-0004-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,8]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["4"],"URL":"https:\/\/doi.org\/10.1007\/s11940-009-0004-x","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,8]]}}}